6:27 PM
 | 
Jan 29, 2013
 |  BC Extra  |  Financial News

Vertex swings to loss on plummeting Incivek sales

As expected, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) swung to a loss on flagging sales of HCV drug Incivek telaprevir. The company reported 4Q12 revenues for of $222.8 million, down 51% from $456.8 million in 4Q11. Full-year sales for the product were $1.16...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >